APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiretroviral Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antiretroviral Drug Market Analysis and Forecast 2026-2032

22 December 2025198 pages

Choose your research edition.

Industry ResearchAntiretroviral Drug Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiretroviral Drug Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Antiretroviral Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiretroviral Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiretroviral Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Antiretroviral Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Antiretroviral Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antiretroviral Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antiretroviral Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antiretroviral Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Antiretroviral Drug include Boehringer-Ingelheim, Bristol-Myer Squibb, CIPLA, Gilead Sciences, ViiV Healthcare, AbbVie, Merck and Johnson and Johnson, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Antiretroviral Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antiretroviral Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Antiretroviral Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antiretroviral Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antiretroviral Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Antiretroviral Drug revenue, projected growth trends, production technology, application and end-user industry.

Antiretroviral Drug Segment by Company

Boehringer-Ingelheim

Bristol-Myer Squibb

CIPLA

Gilead Sciences

ViiV Healthcare

AbbVie

Merck

Johnson and Johnson

Antiretroviral Drug Segment by Type

Multi-Class Drugs Combination

Protease Inhibitors

NRTI

NNRTI

Other

Antiretroviral Drug Segment by Application

Hospital

Pharmaceutical Companies

Other

Antiretroviral Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiretroviral Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiretroviral Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiretroviral Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Antiretroviral Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Antiretroviral Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antiretroviral Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antiretroviral Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Multi-Class Drugs Combination Major Player Table 3. Protease Inhibitors Major Player Table 4. NRTI Major Player Table 5. NNRTI Major Player Table 6. Other Major Player Table 7. Global Antiretroviral Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Major Player Table 9. Pharmaceutical Companies Major Player Table 10. Other Major Player Table 11. Antiretroviral Drug Industry Trends Table 12. Antiretroviral Drug Industry Drivers Table 13. Antiretroviral Drug Industry Opportunities and Challenges Table 14. Antiretroviral Drug Industry Restraints Table 15. Global Antiretroviral Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Antiretroviral Drug Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Antiretroviral Drug Market Share by Region (2021-2026) Table 18. Global Antiretroviral Drug Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Antiretroviral Drug Market Share by Region (2027-2032) Table 20. Global Antiretroviral Drug Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Antiretroviral Drug Revenue Market Share by Players (2021-2026) Table 22. Global Antiretroviral Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Antiretroviral Drug Key Players Headquarters & Area Served Table 24. Global Antiretroviral Drug Players, Product Type & Application Table 25. Global Antiretroviral Drug Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Antiretroviral Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Antiretroviral Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Antiretroviral Drug Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Antiretroviral Drug Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Antiretroviral Drug Revenue Market Share by Type (2021-2026) Table 32. Global Antiretroviral Drug Revenue Market Share by Type (2027-2032) Table 33. Global Antiretroviral Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Antiretroviral Drug Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Antiretroviral Drug Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Antiretroviral Drug Revenue Market Share by Application (2021-2026) Table 37. Global Antiretroviral Drug Revenue Market Share by Application (2027-2032) Table 38. Boehringer-Ingelheim Company Information Table 39. Boehringer-Ingelheim Business Overview Table 40. Boehringer-Ingelheim Antiretroviral Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Boehringer-Ingelheim Antiretroviral Drug Product Portfolio Table 42. Boehringer-Ingelheim Recent Development Table 43. Bristol-Myer Squibb Company Information Table 44. Bristol-Myer Squibb Business Overview Table 45. Bristol-Myer Squibb Antiretroviral Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Bristol-Myer Squibb Antiretroviral Drug Product Portfolio Table 47. Bristol-Myer Squibb Recent Development Table 48. CIPLA Company Information Table 49. CIPLA Business Overview Table 50. CIPLA Antiretroviral Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. CIPLA Antiretroviral Drug Product Portfolio Table 52. CIPLA Recent Development Table 53. Gilead Sciences Company Information Table 54. Gilead Sciences Business Overview Table 55. Gilead Sciences Antiretroviral Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Gilead Sciences Antiretroviral Drug Product Portfolio Table 57. Gilead Sciences Recent Development Table 58. ViiV Healthcare Company Information Table 59. ViiV Healthcare Business Overview Table 60. ViiV Healthcare Antiretroviral Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. ViiV Healthcare Antiretroviral Drug Product Portfolio Table 62. ViiV Healthcare Recent Development Table 63. AbbVie Company Information Table 64. AbbVie Business Overview Table 65. AbbVie Antiretroviral Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. AbbVie Antiretroviral Drug Product Portfolio Table 67. AbbVie Recent Development Table 68. Merck Company Information Table 69. Merck Business Overview Table 70. Merck Antiretroviral Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Merck Antiretroviral Drug Product Portfolio Table 72. Merck Recent Development Table 73. Johnson and Johnson Company Information Table 74. Johnson and Johnson Business Overview Table 75. Johnson and Johnson Antiretroviral Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Johnson and Johnson Antiretroviral Drug Product Portfolio Table 77. Johnson and Johnson Recent Development Table 78. North America Antiretroviral Drug Revenue by Type (2021-2026) & (US$ Million) Table 79. North America Antiretroviral Drug Revenue by Type (2027-2032) & (US$ Million) Table 80. North America Antiretroviral Drug Revenue by Application (2021-2026) & (US$ Million) Table 81. North America Antiretroviral Drug Revenue by Application (2027-2032) & (US$ Million) Table 82. North America Antiretroviral Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 83. North America Antiretroviral Drug Revenue by Country (2021-2026) & (US$ Million) Table 84. North America Antiretroviral Drug Revenue by Country (US$ Million) & (2027-2032) Table 85. Europe Antiretroviral Drug Revenue by Type (2021-2026) & (US$ Million) Table 86. Europe Antiretroviral Drug Revenue by Type (2027-2032) & (US$ Million) Table 87. Europe Antiretroviral Drug Revenue by Application (2021-2026) & (US$ Million) Table 88. Europe Antiretroviral Drug Revenue by Application (2027-2032) & (US$ Million) Table 89. Europe Antiretroviral Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. Europe Antiretroviral Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. Europe Antiretroviral Drug Revenue by Country (US$ Million) & (2027-2032) Table 92. China Antiretroviral Drug Revenue by Type (2021-2026) & (US$ Million) Table 93. China Antiretroviral Drug Revenue by Type (2027-2032) & (US$ Million) Table 94. China Antiretroviral Drug Revenue by Application (2021-2026) & (US$ Million) Table 95. China Antiretroviral Drug Revenue by Application (2027-2032) & (US$ Million) Table 96. Asia Antiretroviral Drug Revenue by Type (2021-2026) & (US$ Million) Table 97. Asia Antiretroviral Drug Revenue by Type (2027-2032) & (US$ Million) Table 98. Asia Antiretroviral Drug Revenue by Application (2021-2026) & (US$ Million) Table 99. Asia Antiretroviral Drug Revenue by Application (2027-2032) & (US$ Million) Table 100. Asia Antiretroviral Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 101. Asia Antiretroviral Drug Revenue by Region (US$ Million) & (2021-2026) Table 102. Asia Antiretroviral Drug Revenue by Region (US$ Million) & (2027-2032) Table 103. SAMEA Antiretroviral Drug Revenue by Type (2021-2026) & (US$ Million) Table 104. SAMEA Antiretroviral Drug Revenue by Type (2027-2032) & (US$ Million) Table 105. SAMEA Antiretroviral Drug Revenue by Application (2021-2026) & (US$ Million) Table 106. SAMEA Antiretroviral Drug Revenue by Application (2027-2032) & (US$ Million) Table 107. SAMEA Antiretroviral Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. SAMEA Antiretroviral Drug Revenue by Country (2021-2026) & (US$ Million) Table 109. SAMEA Antiretroviral Drug Revenue by Country (US$ Million) & (2027-2032) Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Antiretroviral Drug Image Figure 2. Global Antiretroviral Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiretroviral Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Multi-Class Drugs Combination Image Figure 5. Protease Inhibitors Image Figure 6. NRTI Image Figure 7. NNRTI Image Figure 8. Other Image Figure 9. Global Antiretroviral Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Antiretroviral Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Image Figure 12. Pharmaceutical Companies Image Figure 13. Other Image Figure 14. Global Antiretroviral Drug Market Size (US$ Million) & (2021-2032) Figure 15. Global Antiretroviral Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Antiretroviral Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Antiretroviral Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Antiretroviral Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Antiretroviral Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Antiretroviral Drug Revenue Market Share by Type (2021-2032) Figure 22. Global Antiretroviral Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Antiretroviral Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Antiretroviral Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Antiretroviral Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Antiretroviral Drug Revenue Share by Type (2021-2032) Figure 27. North America Antiretroviral Drug Revenue Share by Application (2021-2032) Figure 28. North America Antiretroviral Drug Revenue Share by Country (2021-2032) Figure 29. United States Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Antiretroviral Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Antiretroviral Drug Revenue Share by Type (2021-2032) Figure 34. Europe Antiretroviral Drug Revenue Share by Application (2021-2032) Figure 35. Europe Antiretroviral Drug Revenue Share by Country (2021-2032) Figure 36. Germany Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Antiretroviral Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Antiretroviral Drug Revenue Share by Type (2021-2032) Figure 46. China Antiretroviral Drug Revenue Share by Application (2021-2032) Figure 47. Asia Antiretroviral Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Antiretroviral Drug Revenue Share by Type (2021-2032) Figure 49. Asia Antiretroviral Drug Revenue Share by Application (2021-2032) Figure 50. Asia Antiretroviral Drug Revenue Share by Region (2021-2032) Figure 51. Japan Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Antiretroviral Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Antiretroviral Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA Antiretroviral Drug Revenue Share by Application (2021-2032) Figure 60. SAMEA Antiretroviral Drug Revenue Share by Country (2021-2032) Figure 61. Brazil Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Antiretroviral Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Multi-Class Drugs Combination
  • Protease Inhibitors
  • NRTI
  • NNRTI
  • Other
Applications
  • Hospital
  • Pharmaceutical Companies
  • Other
Companies covered
  • Boehringer-Ingelheim
  • Bristol-Myer Squibb
  • CIPLA
  • Gilead Sciences
  • ViiV Healthcare
  • AbbVie
  • Merck
  • Johnson and Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antiretroviral Drug Market by Type
  3. 1.2.1 Global Antiretroviral Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Multi-Class Drugs Combination
  5. 1.2.3 Protease Inhibitors
  6. 1.2.4 NRTI
  7. 1.2.5 NNRTI
  8. 1.2.6 Other
  9. 1.3 Antiretroviral Drug Market by Application
  10. 1.3.1 Global Antiretroviral Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Pharmaceutical Companies
  13. 1.3.4 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Antiretroviral Drug Market Dynamics
  1. 2.1 Antiretroviral Drug Industry Trends
  2. 2.2 Antiretroviral Drug Industry Drivers
  3. 2.3 Antiretroviral Drug Industry Opportunities and Challenges
  4. 2.4 Antiretroviral Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Antiretroviral Drug Market Perspective (2021-2032)
  2. 3.2 Global Antiretroviral Drug Growth Trends by Region
  3. 3.2.1 Global Antiretroviral Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antiretroviral Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Antiretroviral Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Antiretroviral Drug Revenue by Players
  2. 4.1.1 Global Antiretroviral Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Antiretroviral Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Antiretroviral Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antiretroviral Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Antiretroviral Drug Key Players Headquarters & Area Served
  7. 4.4 Global Antiretroviral Drug Players, Product Type & Application
  8. 4.5 Global Antiretroviral Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Antiretroviral Drug Market CR5 and HHI
  11. 4.6.3 2025 Antiretroviral Drug Tier 1, Tier 2, and Tier 3
5 Antiretroviral Drug Market Size by Type
  1. 5.1 Global Antiretroviral Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Antiretroviral Drug Revenue by Type (2021-2032)
  3. 5.3 Global Antiretroviral Drug Revenue Market Share by Type (2021-2032)
6 Antiretroviral Drug Market Size by Application
  1. 6.1 Global Antiretroviral Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Antiretroviral Drug Revenue by Application (2021-2032)
  3. 6.3 Global Antiretroviral Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Boehringer-Ingelheim
  2. 7.1.1 Boehringer-Ingelheim Company Information
  3. 7.1.2 Boehringer-Ingelheim Business Overview
  4. 7.1.3 Boehringer-Ingelheim Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Boehringer-Ingelheim Antiretroviral Drug Product Portfolio
  6. 7.1.5 Boehringer-Ingelheim Recent Developments
  7. 7.2 Bristol-Myer Squibb
  8. 7.2.1 Bristol-Myer Squibb Company Information
  9. 7.2.2 Bristol-Myer Squibb Business Overview
  10. 7.2.3 Bristol-Myer Squibb Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bristol-Myer Squibb Antiretroviral Drug Product Portfolio
  12. 7.2.5 Bristol-Myer Squibb Recent Developments
  13. 7.3 CIPLA
  14. 7.3.1 CIPLA Company Information
  15. 7.3.2 CIPLA Business Overview
  16. 7.3.3 CIPLA Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 CIPLA Antiretroviral Drug Product Portfolio
  18. 7.3.5 CIPLA Recent Developments
  19. 7.4 Gilead Sciences
  20. 7.4.1 Gilead Sciences Company Information
  21. 7.4.2 Gilead Sciences Business Overview
  22. 7.4.3 Gilead Sciences Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Gilead Sciences Antiretroviral Drug Product Portfolio
  24. 7.4.5 Gilead Sciences Recent Developments
  25. 7.5 ViiV Healthcare
  26. 7.5.1 ViiV Healthcare Company Information
  27. 7.5.2 ViiV Healthcare Business Overview
  28. 7.5.3 ViiV Healthcare Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 ViiV Healthcare Antiretroviral Drug Product Portfolio
  30. 7.5.5 ViiV Healthcare Recent Developments
  31. 7.6 AbbVie
  32. 7.6.1 AbbVie Company Information
  33. 7.6.2 AbbVie Business Overview
  34. 7.6.3 AbbVie Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AbbVie Antiretroviral Drug Product Portfolio
  36. 7.6.5 AbbVie Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck Antiretroviral Drug Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 Johnson and Johnson
  44. 7.8.1 Johnson and Johnson Company Information
  45. 7.8.2 Johnson and Johnson Business Overview
  46. 7.8.3 Johnson and Johnson Antiretroviral Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Johnson and Johnson Antiretroviral Drug Product Portfolio
  48. 7.8.5 Johnson and Johnson Recent Developments
8 North America
  1. 8.1 North America Antiretroviral Drug Revenue (2021-2032)
  2. 8.2 North America Antiretroviral Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Antiretroviral Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Antiretroviral Drug Revenue by Type (2027-2032)
  5. 8.3 North America Antiretroviral Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Antiretroviral Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Antiretroviral Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Antiretroviral Drug Revenue by Application (2027-2032)
  9. 8.5 North America Antiretroviral Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Antiretroviral Drug Revenue by Country
  11. 8.6.1 North America Antiretroviral Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Antiretroviral Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Antiretroviral Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Antiretroviral Drug Revenue (2021-2032)
  2. 9.2 Europe Antiretroviral Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Antiretroviral Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Antiretroviral Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Antiretroviral Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Antiretroviral Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Antiretroviral Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Antiretroviral Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Antiretroviral Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Antiretroviral Drug Revenue by Country
  11. 9.6.1 Europe Antiretroviral Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Antiretroviral Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Antiretroviral Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Antiretroviral Drug Revenue (2021-2032)
  2. 10.2 China Antiretroviral Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Antiretroviral Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Antiretroviral Drug Revenue by Type (2027-2032)
  5. 10.3 China Antiretroviral Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Antiretroviral Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Antiretroviral Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Antiretroviral Drug Revenue by Application (2027-2032)
  9. 10.5 China Antiretroviral Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antiretroviral Drug Revenue (2021-2032)
  2. 11.2 Asia Antiretroviral Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Antiretroviral Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Antiretroviral Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Antiretroviral Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Antiretroviral Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Antiretroviral Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Antiretroviral Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Antiretroviral Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Antiretroviral Drug Revenue by Country
  11. 11.6.1 Asia Antiretroviral Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Antiretroviral Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Antiretroviral Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antiretroviral Drug Revenue (2021-2032)
  2. 12.2 SAMEA Antiretroviral Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Antiretroviral Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Antiretroviral Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Antiretroviral Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Antiretroviral Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Antiretroviral Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Antiretroviral Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Antiretroviral Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Antiretroviral Drug Revenue by Country
  11. 12.6.1 SAMEA Antiretroviral Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Antiretroviral Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Antiretroviral Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst